Aradigm Corporation Announces Data Showing No Occurrence of Primary Lung Cancer in Patients Treated with AERx(R) Insulin Diabetes Management System (iDMS)

HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB:ARDM) (the “Company”) today announced that review of the clinical data by Novo Nordisk a/s (“Novo Nordisk”), with whom the Company had a collaboration for inhaled insulin, revealed no occurrence of primary lung cancer in patients inhaling insulin using the AERx® insulin Diabetes Management System (iDMS). AERx iDMS uses an aqueous formulation of insulin delivered by a hand-held electronic inhaler. Review of the clinical trial data for AERx iDMS revealed no cases of primary lung cancer either in the 2,307 patients treated with AERx iDMS or in the 1,218 patients treated with comparator treatments.

Back to news